Department of Ophthalmology, Hamdard Institute of Medical Sciences and Research, New Delhi, India.
Indian J Ophthalmol. 2024 Jul 1;72(7):1007-1011. doi: 10.4103/IJO.IJO_1393_23. Epub 2024 Mar 8.
To elucidate the efficacy and safety profile of interferon α-2b in vernal keratoconjunctivitis (VKC).
In this prospective interventional study, VKC patients fulfilling the inclusion and exclusion criteria were included and their signs and symptoms were scored based on the Clinical Scoring System. Patients were treated with topical interferon α-2b eye drop (1 MIU/ml) QID dosing for 6 weeks. Changes in symptoms and signs were evaluated at 2, 4, 8 weeks and 6 months after initiating treatment. A higher score meant severe disease, and a decline in score meant improvement in clinical signs and symptoms. Categorical variables were presented in number and percentage (%) and continuous variables as mean ± standard deviation (SD). Post-medication total subjective symptom score (TSSS) and total objective sign score (TOSS) were compared with baseline, and a P- value of <0.05 was considered significant. Possible ocular and systemic complications were evaluated.
The study included 40 patients (32 male and eight female) with a mean age of 8.05 ± 2.33 years. Mean baseline TSSS and TOSS were 6.71 ± 0.564 and 6.59 ± 0.262, respectively, which reduced to 2.71 ± 0.011 ( P = 0.040) and 2.96 ± 0.210 ( P = 0.032), respectively, at 4 weeks and further reduced to 0.42 ± 0.552 and 0.47 ± 0.434, respectively, at 8 weeks. After 6 months of stopping the drug, mean TSSS and TOSS did increase to 2.80 ± 0.820 ( P = 0.044) and 2.50 ± 0.520 ( P = 0.030), respectively, but was still statistically significant improvement compared to the baseline. Also, no ocular or systemic side effects were observed anytime during the study period.
Eye drop interferon α-2b (1 million IU/ml) is a safe and effective option as first-line monotherapy for VKC. No side effects and recurrence were observed for 6 months.
阐明干扰素 α-2b 在春季角结膜炎（VKC）中的疗效和安全性。
在这项前瞻性干预研究中，纳入符合纳入和排除标准的 VKC 患者，并根据临床评分系统对其体征和症状进行评分。患者接受 QID 剂量的局部干扰素 α-2b 滴眼剂（1MIU/ml）治疗 6 周。在开始治疗后 2、4、8 周和 6 个月评估症状和体征的变化。更高的分数表示疾病更严重，分数下降表示临床体征和症状改善。分类变量以数字和百分比（%）表示，连续变量以平均值±标准差（SD）表示。治疗后总主观症状评分（TSSS）和总客观体征评分（TOSS）与基线相比，P 值<0.05 被认为有统计学意义。评估可能出现的眼部和全身并发症。
研究纳入了 40 名患者（32 名男性和 8 名女性），平均年龄为 8.05±2.33 岁。平均基线 TSSS 和 TOSS 分别为 6.71±0.564 和 6.59±0.262，治疗 4 周后分别降至 2.71±0.011（P=0.040）和 2.96±0.210（P=0.032），治疗 8 周后进一步降至 0.42±0.552 和 0.47±0.434。停药 6 个月后，平均 TSSS 和 TOSS 分别增加至 2.80±0.820（P=0.044）和 2.50±0.520（P=0.030），但与基线相比仍有统计学意义的改善。此外，在研究期间的任何时候都没有观察到眼部或全身副作用。
眼部滴注干扰素 α-2b（100 万 IU/ml）是一种安全有效的 VKC 一线单药治疗选择。6 个月内未观察到副作用和复发。
